Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab

This publication has 10 references indexed in Scilit:

• Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
  JAAD Case Reports, 2023
• T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
  Current Opinion in Oncology, 2023
• Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
  Cancers, 2023
• Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
  Drug Design, Development and Therapy, 2023
• Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
  New England Journal of Medicine, 2022
• Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
  Blood, 2020
• Pityriasis lichenoides-like drug reaction: A clinical histopathologic study of 10 cases
  Dermatology Online Journal, 2017
• Pityriasis lichenoides chronica in a patient affected by multiple myeloma
  Journal of the European Academy of Dermatology and Venereology, 2007
• Pityriasis lichenoides and its subtypes
  Journal of the American Academy of Dermatology, 2006
• Pityriasis lichenoides: A clonal T-cell lymphoproliferative disorder
  Human Pathology, 2002